AFT Forsyth & Company’s Biogen BIIB Stock Holding History

AFT Forsyth & Company’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	$14K	Hold	60	–	–	0.02%	254
2013 Q2	$13K	Buy	+60	New	+$12.8K	0.02%	238

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

AFT Forsyth & Company's BIIB Position: Q3 2013 in Review

AFT Forsyth & Company held its Biogen (BIIB) position steady in Q3 2013 at 60 shares worth $14K. The position accounts for 0.02% of the portfolio, ranked #254.

AFT Forsyth & Company first reported a position in BIIB in Q2 2013 and has held it in 2 quarters since. 656 funds tracked by Wall St. Rank hold BIIB as of Q3 2013.

AFT Forsyth & Company held 60 shares of Biogen worth $14K as of Q3 2013.
AFT Forsyth & Company left its Biogen share count unchanged in Q3 2013.
Biogen made up 0.02% of AFT Forsyth & Company's portfolio in Q3 2013, its #254 holding.
AFT Forsyth & Company first reported a position in Biogen in Q2 2013 and has held it in 2 quarters since.
656 funds tracked by Wall St. Rank held Biogen as of Q3 2013.

Based on AFT Forsyth & Company's 13F filing for Q3 2013, filed 8 Nov 2013.